Q2 Earnings Estimate for LRMR Issued By Wedbush

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Wedbush issued their Q2 2026 earnings per share estimates for shares of Larimar Therapeutics in a research report issued on Wednesday, April 30th. Wedbush analyst L. Chico forecasts that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.48) EPS, FY2028 earnings at $0.75 EPS and FY2029 earnings at $4.83 EPS.

Other equities analysts have also recently issued research reports about the stock. Citigroup reissued a “buy” rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Truist Financial assumed coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price objective for the company. HC Wainwright upped their target price on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 25th. Guggenheim reiterated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, Robert W. Baird decreased their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, March 25th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $19.63.

Larimar Therapeutics Stock Up 3.8 %

Shares of NASDAQ LRMR opened at $2.97 on Friday. The firm has a market cap of $190.16 million, a PE ratio of -2.58 and a beta of 0.91. The company’s fifty day simple moving average is $2.36 and its 200 day simple moving average is $4.23. Larimar Therapeutics has a 12-month low of $1.61 and a 12-month high of $11.20.

Larimar Therapeutics (NASDAQ:LRMR) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Trading of Larimar Therapeutics

Institutional investors have recently made changes to their positions in the company. Fi3 FINANCIAL ADVISORS LLC boosted its holdings in Larimar Therapeutics by 16.7% during the fourth quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock worth $92,000 after purchasing an additional 3,411 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Larimar Therapeutics by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after buying an additional 3,425 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Larimar Therapeutics by 21.9% during the 3rd quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after buying an additional 3,549 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company’s stock worth $137,000 after buying an additional 3,877 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Larimar Therapeutics by 8.1% in the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company’s stock valued at $206,000 after acquiring an additional 3,980 shares in the last quarter. Institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.